Table 3.

Changes from baseline to end of treatment (EoT) in bladder diary variables

Variable	Population	Mirabegron				Tolterodine					Period-by-treatment interaction p value
		No. of patients	Baseline, mean (SE)	EoT, mean (SE)	Adjusted change from baseline to EoT, mean (SE), [95% CI]	No. of patients	Baseline, mean (SE)	EoT, mean (SE)	Adjusted change from baseline to EoT, mean (SE), [95% CI]	Adjusted difference vs. mirabegron, mean (SE) [95% CI]
Incontinence episodes/24h	FAS-I	248	3.70 (0.29) [n = 245]	2.07 (0.25) [n=246]	–1.51 (0.19) [−1.89, −1.13]	240	3.69 (0.30) [n=238]	2.02 (0.23) [n=235]	−1.46 (0.19) (−1.84, −1.07)	0.05 (0.224) [−0.39, 0.49]	0.971
Number of micturitions/24h	FAS	341	10.34 (0.18) [n=336]	8.25 (0.18) [n=336]	–2.06 (0.19) [−2.44, −1.68]	336	10.08 (0.21) [n=334]	8.13 (0.19) [n=329]	−1.95 (0.20) [−2.33, −1.57]	0.11 (0.20) [−0.28, 0.50]	0.211
Urgency incontinence episodes/24h	FAS-I	248	3.20 (0.28) [n=245]	1.61 (0.22) [n=246]	–1.42 (0.20) [−1.81, −1.02]	240	3.16 (0.28) [n=238]	1.55 (0.21) [n=235]	−1.37 (0.20) [−1.76, −0.97]	0.05 (0.20) [−0.35, 0.45]
Number of urgency episodes (PPIUS grade 3 or 4)/24h	FAS	341	4.39 (0.24) [n=336]	2.14 (0.19) [n=336]	–2.26 (0.19) [−2.64, −1.88]	336	4.23 (0.24) [n=334]	2.13 (0.19) [n=329]	−2.13 (0.19) [−2.51, −1.75]	0.13 (0.17) [−0.20, 0.46]
Number of nocturia episodes/24h	FAS	341	1.62 (0.06) [n=277]	1.27 (0.06) [n=272]	–0.26 (0.06) (−0.38, −0.14)	336	1.47 (0.06) [n=280]	1.22 (0.05) [n=273]	−0.25 (0.06) (−0.37, −0.13)	0.01 (0.07) [−0.13, 0.15]

FAS Full analysis set, FAS-I Full analysis set–incontinence